Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI platform aims to help disabled adults manage chronic diseases

NCT ID NCT05481593

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new AI-assisted telehealth program designed to help adults with physical disabilities manage chronic conditions like heart disease, diabetes, and lung disease. Researchers wanted to see if the platform could improve quality of life, physical activity, and medication adherence. The study involved 212 participants and focused on making the technology accessible and family-friendly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

212 people

The number who actually took part.

Started

Feb 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Diagnosis of heart disease, chronic lung disease, or Type 2 diabetes * Living with a permanent physical disability (i.e., spina bifida, multiple sclerosis, stroke,) * Have the ability to converse in and read English * Availability of a smartphone or computer Exclusion Criteria: * Current enrollment in any structured intervention * Severe cognitive impairment * Severe untreated depression in the past 6 months * Major cardiac event in the past 12 months * Uncontrolled blood pressure * Resting tachycardia * Renal failure * Severe peripheral neuropathy * Active treatment for cancer in the past 12 months * Having both visual and hearing impairments (either of them is fine)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic condition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Disease heart disorder Multiple Chronic Conditions type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.